title: Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.
abstract: Effects of cannabinoid receptor 1 (CB1R) blockade were observed by comparing 9-day and 6-week SR141716 treatments in monosodium glutamate (MSG)-induced hypometabolic and hypothalamic obesity (HO) in rats for the first time and molecular mechanisms were investigated. Compared with normal rats, the MSG rats display typical symptoms of the metabolic syndrome, i.e., excessive abdominal obesity, hypertriglyceridemia, hyperinsulinemia, insulin resistance, and hepatic steatosis, but with lower food intake. Although both the 9-day and 6-week treatments with the specific CB1R antagonist SR141716 effectively lowered body weight, intraperitoneal adipose tissue mass, serum triglyceride (TG), and insulin level, the effect of chronic treatment is more impressive. Moreover, serum cholesterol, free fatty acids (FFA), fasted and postprandial blood glucose, and insulin insensitivity were more effectively improved by 6-week exposure to SR141716, whereas hypophagia was only effective within the initial 2 weeks. In addition, hepatic steatosis as well as hepatic and adipocyte morphology was improved. Western blot analysis revealed that the markedly increased CB1R expression and decreased insulin receptor (INR) expression in liver and adipose tissues were effectively corrected by SR141716. Consistent with this, deregulated gene expression of lipogenesis and lipolysis as well as glucose metabolic key enzymes were also restored by SR141716. In conclusion, based on present data we found that: (1) alteration of the hypothalamus in MSG rats leads to a lower expression of INR in crucially insulin-targeted tissues and hyperinsulinemia that was reversed by SR141716, (2) the abnormally increased expression of CB1R in liver and adipose tissues plays a vital role in the pathophysiological process of MSG rats, and (3) chronic CB1R blockade leads to a sustained improvement of the metabolic dysfunctions of MSG rats.
authors.affiliation: Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Zhenhua
authors.initials: Z
authors.lastname: Chen
authors.forename: Nina
authors.initials: N
authors.lastname: Xue
authors.forename: Zhibing
authors.initials: Z
authors.lastname: Zheng
authors.forename: Song
authors.initials: S
authors.lastname: Li
authors.forename: Lili
authors.initials: L
authors.lastname: Wang
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000818:Animals; D000831:Animals, Newborn; D063387:Cannabinoid Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D005234:Fatty Liver / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005260:Female; D018149:Glucose Intolerance / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D007333:Insulin Resistance; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D009765:Obesity / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D011972:Receptor, Insulin / Q000378:metabolism; D000077285:Rimonabant; D012970:Sodium Glutamate
chemical_list: D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D011972:Receptor, Insulin; D000077285:Rimonabant; D012970:Sodium Glutamate